Signed in · PRO

Guidance history, every release

Gilead Sciences (GILD) · 8 releases, Nov 6, 2024 to Aug 4, 2026 · rows are metrics, columns are releases

Raised · a change from the previous releaseSame · restated unchanged— · not stated in that releaseEvery value links to its sentence in the filing

Metric	Nov 6, 2024 FY24 Q3	Feb 11, 2025 FY24 Q4	Apr 24, 2025 FY25 Q1	Aug 7, 2025 FY25 Q2	Oct 30, 2025 FY25 Q3	Feb 10, 2026 FY25 Q4	May 7, 2026 FY26 Q1	Aug 4, 2026 FY26 Q2
For FY2030
Planned investment in the U.S.	—	—	—	—	New“$32 billion”	—	—	—
Planned U.S. manufacturing and R&D investment	—	—	—	—	New“$32 billion”	—	—	—
For FY2026
Diluted EPS	—	—	—	—	—	New“$6.75 - $7.15”	—	—
GAAP projected operating income	—	—	—	—	—	New“$11,400 - $11,900”	—	—
GAAP projected operating income (loss) (in millions)	—	—	—	—	—	—	—	New“$(2,250) - $(1,850)”
GAAP projected product gross margin	—	—	—	—	—	New“~ 79.0%”	—	Reiterated“~ 79.0%”
Non-GAAP diluted EPS	—	—	—	—	—	New“$8.45 - $8.85”	—	—
Non-GAAP projected operating income	—	—	—	—	—	New“$13,800 - $14,300”	—	—
Non-GAAP projected operating income (in millions)	—	—	—	—	—	—	—	New“$2,900 - $3,300”
Non-GAAP projected product gross margin	—	—	—	—	—	New“~ 87.0%”	—	Reiterated“~ 87.0%”
Diluted loss per share	—	—	—	—	—	—	—	New“$ (3.75) $ (3.40)”
GAAP projected effective tax rate	—	—	—	—	—	New“~ 21%”	—	Lowered“~ (80%) - (90%)”
GAAP projected effective tax rate excluding Acquired IPR&D expenses	—	—	—	—	—	—	—	New“~21%”
Non-GAAP diluted loss per share	—	—	—	—	—	—	—	New“$ (0.65) $ (0.30)”
Non-GAAP projected effective tax rate	—	—	—	—	—	New“~ 20%”	—	Raised“~ 140% - 115%”
Non-GAAP projected effective tax rate excluding Acquired IPR&D expenses	—	—	—	—	—	—	—	New“~20%”
Product sales (in millions)	—	—	—	—	—	—	—	New“$ 30,100 $ 30,400”
Product sales excluding Veklury (in millions)	—	—	—	—	—	—	—	New“$ 29,800 $ 30,100”
Quarterly dividend declared	—	—	—	—	—	—	—	New“$0.82 per share”
Quarterly dividend declared	—	—	—	—	—	—	New“$0.82 per share”	—
Quarterly dividend declared	—	—	—	—	—	New“$0.82 per share”	—	—
Quarterly dividend of common stock	—	—	—	—	—	—	—	New“$0.82 per share”
Quarterly dividend of common stock	—	—	—	—	—	—	New“$0.82 per share”	—
Quarterly dividend of common stock	—	—	—	—	—	New“$0.82 per share”	—	—
Veklury (in millions)	—	—	—	—	—	—	—	New“~ $300”
For FY2025
Diluted EPS	—	—	New“$ 5.65” – “$ 6.05”	—	Raised“$ 6.65 $ 6.85”	—	—	—
GAAP projected diluted EPS	—	New“$5.95 - $6.35”	—	—	—	—	—	—
GAAP projected operating income	—	New“$10,200 - $10,700”	Reiterated“$10,200 - $10,700”	Narrowed“$10,300 - $10,700”	Narrowed“$10,300 - $10,600”	—	—	—
GAAP projected product gross margin	—	New“77.0% - 78.0%”	Reiterated“77.0% - 78.0%”	Raised“~ 78.0%”	Reiterated“~ 78.0%”	—	—	—
Non-GAAP diluted EPS	—	—	New“$ 7.70” – “$ 8.10”	—	Raised“$ 8.05 $ 8.25”	—	—	—
Non-GAAP projected diluted EPS	—	New“$7.70 - $8.10”	—	—	—	—	—	—
Non-GAAP projected operating income	—	New“$12,700 - $13,200”	Reiterated“$12,700 - $13,200”	Raised“$13,000 - $13,400”	Narrowed“$13,100 - $13,400”	—	—	—
Non-GAAP projected product gross margin	—	New“85.0% - 86.0%”	Reiterated“85.0% - 86.0%”	Raised“~ 86.0%”	Reiterated“~ 86.0%”	—	—	—
GAAP projected effective tax rate	—	New“~ 20%”	Raised“~ 21%”	Reiterated“~ 21%”	Lowered“~ 16%”	—	—	—
Non-GAAP projected effective tax rate	—	New“~ 19%”	Reiterated“~ 19%”	Reiterated“~ 19%”	Reiterated“~ 19%”	—	—	—
Potential launch of lenacapavir for HIV PrEP	—	New“Summer 2025”	—	—	—	—	—	—
Product sales	—	—	New“$ 28,200” – “$ 28,600”	—	Raised“$ 28,400 $ 28,700”	—	—	—
Product sales excluding Veklury	—	—	New“$ 26,800” – “$ 27,200”	—	Raised“$ 27,400 $ 27,700”	—	—	—
Quarterly dividend	—	—	—	New“$0.79 per share”	—	—	—	—
Quarterly dividend declared	—	—	—	—	New“$0.79”	—	—	—
Quarterly dividend declared	—	New“$0.79 per share”	—	—	—	—	—	—
Quarterly dividend declared for Q2 2025	—	—	New“$0.79 per share of common stock”	—	—	—	—	—
Quarterly dividend of common stock	—	—	—	—	New“$0.79 per share”	—	—	—
Quarterly dividend of common stock	—	—	—	New“$0.79 per share”	—	—	—	—
Quarterly dividend of common stock	—	—	New“$0.79 per share”	—	—	—	—	—
Quarterly dividend of common stock	—	New“$0.79 per share”	—	—	—	—	—	—
Veklury	—	—	—	New“$1,000”	Reiterated“$ 1,000 $ 1,000”	—	—	—
Veklury (High End)	—	—	New“$ 1,400”	—	—	—	—	—
For FY2024
Quarterly dividend	New“$0.77 per share”	—	—	—	—	—	—	—
Quarterly dividend of common stock	New“$0.77 per share”	—	—	—	—	—	—	—
Veklury	New“$1,800”	—	—	—	—	—	—	—
No period stated
Diluted (loss) earnings per share	—	—	—	—	—	—	New“$ (3.25)”	—
Diluted EPS	New“$ 0.05”	Changed“$ 5.95”	Lowered“$ 5.65”	Raised“$ 5.85”	Raised“$ 6.65”	Raised“$ 6.75”	—	—
Non-GAAP diluted (loss) earnings per share	—	—	—	—	—	—	New“$ (1.05)”	—
Non-GAAP diluted EPS	New“$ 4.25”	Raised“$ 7.70”	Reiterated“$ 7.70”	Raised“$ 7.95”	Raised“$ 8.05”	Raised“$ 8.45”	—	—
Diluted loss per share	—	—	—	—	—	—	—	New“$ (3.75)”
Non-GAAP diluted loss per share	—	—	—	—	—	—	—	New“$ (0.65)”
Product sales	New“$ 27,800”	Raised“$ 28,200”	Reiterated“$ 28,200”	Raised“$ 28,300”	Raised“$ 28,400”	Raised“$ 29,600”	Raised“$ 30,000”	Raised“$ 30,100”
Product sales excluding Veklury	New“$ 26,000”	Raised“$ 26,800”	Reiterated“$ 26,800”	Raised“$ 27,300”	Raised“$ 27,400”	Raised“$ 29,000”	Raised“$ 29,400”	Raised“$ 29,800”
Stock repurchase program authorization	—	—	—	New“$6.0 billion”	—	—	—	—
Veklury	—	New“$ 1,400”	Reiterated“$ 1,400”	—	Lowered“$ 1,000”	Lowered“$ 600”	Reiterated“$ 600”	Lowered“~ $300”

Values in quotation marks are the company’s words. Change labels compare each statement with the same metric and target year in the previous release. HighGravityData does not judge whether guidance was met.